Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Publication Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Certara2016年11月15日
IVIVC Software – Achieving Regulatory, Formulation and Manufacturing Success Brochure IVIVC Software – Achieving Regulatory, Formulation and Manufacturing Success In vitro-in vivo correlation (IVIVC) is an important, predictive mathematical tool in drug development, used…Certara2016年11月8日
Certara Establishes Phoenix PK/PD Centers of Excellence in China and Japan Press Release サターラ、中国と日本にPK/PDセンター・オブ・エクセレンス(COE)を設立 PRINCETON, NJ – Oct. 13, 2016 – Certara, the leading provider of decision support technology…Certara2016年10月13日
Profiling the Relationship Between Tumor-associated Macrophages and Pharmacokinetics of Liposomal Agents in Preclinical Murine Models Publication Profiling the Relationship Between Tumor-associated Macrophages and Pharmacokinetics of Liposomal Agents in Preclinical Murine Models Certara2016年10月5日
A Study to Examine the Relationship Between Metritis Severity and Depletion of Oxytetracycline in Plasma and Milk after Intrauterine Infusion Publication A Study to Examine the Relationship Between Metritis Severity and Depletion of Oxytetracycline in Plasma and Milk after Intrauterine Infusion Metritis is a frequent problem in postpartum dairy cows. Intrauterine therapy with the antimicrobial oxytetracycline…Certara2016年10月1日
Gulp1 is Associated with the Pharmacokinetics of PEGylated Liposomal Doxorubicin (PLD) in Inbred Mouse Strains Publication Gulp1 is Associated with the Pharmacokinetics of PEGylated Liposomal Doxorubicin (PLD) in Inbred Mouse Strains Certara2016年10月1日
Arming Adherence-based Drug Development with Pharmacometrics Blog Arming Adherence-based Drug Development with Pharmacometrics The time is right to explore how sensor-enabled digital adherence monitoring systems can benefit patients,…Certara2016年9月12日
Phoenix NLME, The Modern PK/PD Modeling Software for Today’s Scientists Brochure Phoenix NLME ― 現代のサイエンティストのための最新PK/PDモデリングソフトウェア Phoenix NLMEは、使いやすく、習得しやすいPK/PDモデリングソフトウェアです。Built from the…Certara2016年9月12日
Rare Disease and Orphan Drug Development Brochure 希少疾病と希少疾病用医薬品の開発 There are 7,000 rare diseases impacting 350 million patients worldwide, yet only 300 of these…Certara2016年8月3日
Population Pharmacokinetics of Bevacizumab in Cancer Patients with External Validation Publication Population Pharmacokinetics of Bevacizumab in Cancer Patients with External Validation Certara2016年8月1日